C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Hayashi, Tsuguru, Shibata, Michihiko, Oe, Shinji, Miyagawa, Koichiro, Honma, Yuichi, Harada, Masaru
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://ncbi.nlm.nih.gov/pubmed/33351844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares